|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
104,690,000 |
Market
Cap: |
110.01(B) |
Last
Volume: |
507,716 |
Avg
Vol: |
759,306 |
52
Week Range: |
$692.45 - $1071.19 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 150 |
Guru Rank Value : 6.9 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) ![](../../images/information.jpg) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
192,108 |
259,662 |
311,759 |
469,743 |
Total Sell Value |
$188,697,290 |
$251,749,241 |
$294,950,701 |
$405,465,351 |
Total People Sold |
7 |
14 |
16 |
18 |
Total Sell Transactions |
18 |
45 |
67 |
128 |
End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Yancopoulos George |
President and CSO |
|
2019-11-18 |
4 |
GD |
$0.00 |
$0 |
I/I |
325,986 |
0 |
|
- |
|
Yancopoulos George |
President and CSO |
|
2019-11-18 |
4 |
GA |
$0.00 |
$0 |
D/D |
325,986 |
325,986 |
|
- |
|
Yancopoulos George |
President and CSO |
|
2019-11-14 |
4 |
GD |
$0.00 |
$0 |
I/I |
2,366 |
325,989 |
|
- |
|
Vagelos P Roy |
Chairman of the Board |
|
2019-11-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
40,681 |
347,824 |
|
- |
|
Brown Michael S |
Director |
|
2019-11-12 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,000 |
11,349 |
|
- |
|
Brown Michael S |
Director |
|
2019-11-12 |
4 |
AS |
$349.00 |
$1,570,500 |
D/D |
(4,500) |
323 |
|
- |
|
Brown Michael S |
Director |
|
2019-11-12 |
4 |
OE |
$273.67 |
$1,231,515 |
D/D |
4,500 |
4,823 |
|
- |
|
Stahl Neil |
EVP Research and Development |
|
2019-11-08 |
4 |
S |
$330.56 |
$2,492,888 |
D/D |
(7,364) |
22,455 |
|
- |
|
Goldstein Joseph L |
Director |
|
2019-11-08 |
4 |
S |
$340.44 |
$340,440 |
D/D |
(1,000) |
10,323 |
|
- |
|
Vagelos P Roy |
Chairman of the Board |
|
2019-10-02 |
4 |
GD |
$0.00 |
$0 |
I/I |
764 |
144,897 |
|
- |
|
Sanofi-Aventis |
|
|
2019-09-10 |
4 |
S |
$281.15 |
$48,611,804 |
D/D |
(172,904) |
20,550,813 |
|
- |
|
Yancopoulos George |
President and CSO |
|
2019-08-05 |
4 |
GA |
$0.00 |
$0 |
I/I |
75,036 |
328,352 |
|
- |
|
Yancopoulos George |
President and CSO |
|
2019-08-05 |
4 |
GD |
$0.00 |
$0 |
I/I |
75,036 |
0 |
|
- |
|
Vagelos P Roy |
Chairman of the Board |
|
2019-07-02 |
4 |
GD |
$0.00 |
$0 |
I/I |
669 |
145,661 |
|
- |
|
Yancopoulos George |
President and CSO |
|
2019-06-13 |
4 |
GD |
$0.00 |
$0 |
I/I |
500,000 |
253,316 |
|
- |
|
Yancopoulos George |
President and CSO |
|
2019-06-13 |
4 |
GA |
$0.00 |
$0 |
I/I |
500,000 |
500,000 |
|
- |
|
Stahl Neil |
EVP Research and Development |
|
2019-05-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,300 |
21,150 |
|
- |
|
Vagelos P Roy |
Chairman of the Board |
|
2019-05-24 |
4 |
D |
$313.64 |
$25,142,637 |
D/D |
(80,164) |
388,505 |
|
- |
|
Vagelos P Roy |
Chairman of the Board |
|
2019-05-24 |
4 |
OE |
$21.25 |
$3,268,080 |
D/D |
153,792 |
468,669 |
|
- |
|
Goldstein Joseph L |
Director |
|
2019-05-15 |
4 |
S |
$305.93 |
$305,930 |
D/D |
(1,000) |
11,323 |
|
- |
|
Fenimore Christopher R. |
VP Controller |
|
2019-04-18 |
4 |
GA |
$0.00 |
$0 |
I/I |
350 |
1,897 |
|
- |
|
Fenimore Christopher R. |
VP Controller |
|
2019-04-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
350 |
7,096 |
|
- |
|
Fenimore Christopher R. |
VP Controller |
|
2019-04-18 |
4 |
OE |
$21.25 |
$7,438 |
D/D |
350 |
7,446 |
|
- |
|
Vagelos P Roy |
Chairman of the Board |
|
2019-04-15 |
4 |
GD |
$0.00 |
$0 |
I/I |
514 |
146,330 |
|
- |
|
Schleifer Leonard S |
President & CEO |
|
2019-03-21 |
4 |
OE |
$21.25 |
$2,125 |
D/D |
100 |
424,062 |
|
- |
|
2430 Records found
|
|
Page 37 of 98 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|